Analysis of Limiters for ADITYA Tokamak

ADITYA Tokamak is a medium size ohmically heated tokamak. The hot plasma interacts with the vacuum vessel wall introducing impurities in the plasma and also damages the vacuum vessel wall. Limiter is used to reduce plasma - wall interaction and protect the vacuum vessel wall as well as inside components. It also controls impurity generation. ADITYA has a set of two types of limiters (i) Safety limiter (ii) a Poloidal limiter. Formally all the limiters are made of shaped graphite tiles fixed on stainless steel base plates. But graphite tiles are responsible for low Z impurities in plasma. To avoid these low Z impurities Molybdenum tiles are suggested. In this paper, we are going to present ansys analysis of surface temperature rise of molybdenum tiles compared to graphite tiles when used as Poloidal Limiter during plasma discharges in Aditya tokamak. The analysis is carried by ANSYS 11.0 software using Transient Thermal Analysis module. The results are compared with experimental results for graphite tiles. The graphite and molybdenum tiles are analyzed under same conditions

Increased deep sleep in a medication-free, detoxified female offender with schizophrenia, alcoholism and a history of attempted homicide: Case report

BACKGROUND: Psychiatric sleep research has attempted to identify diagnostically sensitive and specific sleep patterns associated with particular disorders. Both schizophrenia and alcoholism are typically characterized by a severe sleep disturbance associated with decreased amounts of slow wave sleep, the physiologically significant, refreshing part of the sleep. Antisocial behaviour with severe aggression, on the contrary, has been reported to associate with increased deep sleep reflecting either specific brain pathology or a delay in the normal development of sleep patterns. The authors are not aware of previous sleep studies in patients with both schizophrenia and antisocial personality disorder. CASE PRESENTATION: The aim of the present case-study was to characterize the sleep architecture of a violent, medication-free and detoxified female offender with schizophrenia, alcoholism and features of antisocial personality disorder using polysomnography. The controls consisted of three healthy, age-matched women with no history of physical violence. The offender's sleep architecture was otherwise very typical for patients with schizophrenia and/or alcoholism, but an extremely high amount of deep sleep was observed in her sleep recording. CONCLUSIONS: The finding strengthens the view that severe aggression is related to an abnormal sleep pattern with increased deep sleep. The authors were able to observe this phenomenon in an antisocially behaving, violent female offender with schizophrenia and alcohol dependence, the latter disorders previously reported to be associated with low levels of slow wave sleep. New studies are, however, needed to confirm and explain this preliminary finding

COVID‐19 prevalence among health‐care workers of Gastroenterology department: An audit from a tertiary‐care hospital in India

Abstract Background and Aim In the present coronavirus disease‐19 (COVID‐19) era, health‐care workers (HCWs) warrant special attention because of their higher risk and potential to transmit the disease. Gastroenterology services include emergency and critical care along with the endoscopy procedures, which have aerosol‐generating potential. This study was aimed at auditing the COVID‐19 impact on HCWs working in the Gastroenterology department of our hospital. Methods The COVID‐19 status of 117 HCWs was collected using either polymerase chain reaction (PCR) or Immunoglobulin G (IgG) seroassay. COVID‐19 positivity was correlated with demographic characteristics, job profile, area of work, and medical history. Results Thirty‐eight HCWs (32.48%) showed evidence of COVID‐19 using PCR (23.93%) or only IgG assay (8.55%). Endoscopy technicians (68.75%) exhibited significantly higher (P = 0.003) COVID‐19 incidence compared to doctors (20.69%). Those working in the critical care units exhibited a trend toward higher COVID‐19 incidence (42.86%). None of the six HCWs who received adequate hydroxychloroquine prophylaxis developed evidence of COVID‐19. All the HCWs with COVID‐19 disease recovered. However, there was a considerable loss of “man‐days.” Conclusions In our setting, we observed a high COVID‐19 risk for HCWs working in the Gastroenterology department, with the highest risk among the endoscopy technicians. A more stringent triaging and pretesting of patients, as well as HCWs, might decrease the risk of COVID‐19. Further multicenter studies are needed to evaluate the risk and related parameters

Rectal INdomethacin, oral TacROlimus, or their combination for the prevention of post-ERCP pancreatitis (INTRO Trial): Protocol for a randomized, controlled, double-blinded trial.

BACKGROUND: Acute pancreatitis remains the most common and morbid complication of endoscopic retrograde cholangiopancreatography (ERCP). The use of rectal indomethacin and pancreatic duct stenting has been shown to reduce the incidence and severity of post-ERCP pancreatitis (PEP), but these interventions have limitations. Recent clinical and translational evidence suggests a role for calcineurin inhibitors in the prevention of pancreatitis, with multiple retrospective case series showing a reduction in PEP rates in tacrolimus users. METHODS: The INTRO trial is a multicenter, international, randomized, double-blinded, controlled trial. A total of 4,874 patients undergoing ERCP will be randomized to receive either oral tacrolimus (5 mg) or oral placebo 1-2 h before ERCP, and followed for 30 days post-procedure. Blood and pancreatic aspirate samples will also be collected in a subset of patients to quantify tacrolimus levels. The primary outcome of the study is the incidence of PEP. Secondary endpoints include the severity of PEP, ERCP-related complications, adverse drug events, length of hospital stay, cost-effectiveness, and the pharmacokinetics, pharmacodynamics, and pharmacogenomics of tacrolimus immune modulation in the pancreas. CONCLUSIONS: The INTRO trial will assess the role of calcineurin inhibitors in PEP prophylaxis and develop a foundation for the clinical optimization of this therapeutic strategy from a pharmacologic and economic standpoint. With this clinical trial, we hope to demonstrate a novel approach to PEP prophylaxis using a widely available and well-characterized class of drugs. TRIAL REGISTRATION: NCT05252754, registered on February 14, 2022